AyÅ**ÿ**gül Aksan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8531022/publications.pdf

Version: 2024-02-01

		1170033	1051228
32	292	9	16
papers	citations	h-index	g-index
34	34	34	355
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Relevance of Biotin Deficiency in Patients with Inflammatory Bowel Disease and Utility of Serum 3 Hydroxyisovaleryl Carnitine as a Practical Everyday Marker. Journal of Clinical Medicine, 2022, 11, 1118.	1.0	9
2	Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in Therapy, 2021, 38, 660-677.	1.3	13
3	Diagnostic utility of low hemoglobin density to detect iron deficiency in patients with inflammatory bowel disease. Annals of Gastroenterology, 2021, 34, 521-527.	0.4	2
4	Zinc Protoporphyrin Is a Reliable Marker of Functional Iron Deficiency in Patients with Inflammatory Bowel Disease. Diagnostics, 2021, 11, 366.	1.3	5
5	Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Review of Hematology, 2021, , 1-2.	1.0	О
6	Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 541-552.	0.7	11
7	Osteopontin Levels in Human Milk Are Related to Maternal Nutrition and Infant Health and Growth. Nutrients, 2021, 13, 2670.	1.7	13
8	A Response to: Letter to the Editor Regarding †Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'. Advances in Therapy, 2021, , 1.	1.3	O
9	Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 316-322.	0.6	13
10	P585 Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: Preliminary results from the IBD subgroup analysis. Journal of Crohn's and Colitis, 2020, 14, S490-S490.	0.6	6
11	Measuring Vitamin D Status in Chronic Inflammatory Disorders: How does Chronic Inflammation Affect the Reliability of Vitamin D Metabolites in Patients with IBD?. Journal of Clinical Medicine, 2020, 9, 547.	1.0	12
12	Orale Eisensubstitution (therapie?) bei CED - weniger ist meist mehr?. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	1
13	How useful are anthropometric measurements as predictive markers for elevated blood pressure in adolescents in different gender?. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 1203-1211.	0.4	11
14	The role of adipokines in the improvement of diabetic and cardiovascular risk factors within a 52-week weight-loss programme for obesity. Obesity Research and Clinical Practice, 2019, 13, 440-447.	0.8	6
15	P168 Adjusting serum ferritin concentrations to remove the effects of acute-phase response in patients with IBD and iron deficiency: is using C-reactive protein sufficient?. Journal of Crohn's and Colitis, 2019, 13, S173-S173.	0.6	O
16	P433 Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S325-S326.	0.6	0
17	Percutaneous endoscopic gastrostomy (PEG): a practical approach for long term management. BMJ: British Medical Journal, 2019, 364, k5311.	2.4	12
18	Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy, 2019, 36, 1817-1820.	1.3	0

#	Article	IF	CITATIONS
19	P701 The comparative safety of different intravenous iron preparations in inflammatory bowel disease: a systematic review and network meta-analysis. Journal of Crohn's and Colitis, 2019, 13, S471-S472.	0.6	2
20	P719 Update of a network meta-analysis of efficacy and safety of different intravenous iron compounds in patients with IBD and anaemia. Journal of Crohn's and Colitis, 2019, 13, S481-S481.	0.6	O
21	An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2019, 13, 95-97.	1.4	5
22	Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease. Clinical Laboratory, 2019, 65, .	0.2	7
23	Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. Journal of Crohn's and Colitis, 2018, 12, 826-834.	0.6	10
24	Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scandinavian Journal of Gastroenterology, 2018, 53, 1059-1065.	0.6	16
25	Editorial: which iron preparation for patients with <scp>IBD</scp> ? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 195-196.	1.9	3
26	Systematic review with network metaâ€analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1303-1318.	1.9	87
27	Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies—authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 705-706.	1.9	4
28	Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opinion on Pharmacotherapy, 2017, 18, 1721-1737.	0.9	25
29	Letter: inconsistency in reporting of hypophosphataemia after intravenous iron—authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 643-644.	1.9	O
30	Adherence to a Gluten-Free Diet and Frequency of Inadvertent Consumption of Gluten-Containing Foods in Adult Patients With Celiac Disease in Ankara, Turkey. American Journal of Gastroenterology, 2017, 112, S662.	0.2	0
31	First Results From the Celiac Disease Health-Related Quality of Life Questionnaire in Turkey: Potential Impact of Nutrition Status on Health-Related Quality of Life in Adult Patients With Celiac Disease. American Journal of Gastroenterology, 2017, 112, S662.	0.2	O
32	Validation of the Turkish version of the Celiac Disease Questionnaire (CDQ). Health and Quality of Life Outcomes, 2015, 13, 82.	1.0	19